Author:
Muccini Camilla,Diotallevi Sara,Lolatto Riccardo,Piromalli Girolamo,Spagnuolo Vincenzo,Castagna Antonella
Reference5 articles.
1. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts
2. One-year of long-acting cabotegravir and rilpivirine in people with HIV and a long exposure to antiretroviral therapy: data from the SCohoLART study;Muccini;Open Forum Infect Dis,2024
3. Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV;Damas;Clin Infect Dis,2024
4. The LDL cumulative exposure hypothesis: evidence and practical applications;Ference;Nat Rev Cardiol,2024
5. Tan DHS, Antinori A, Eu B, Galindo MJ, Kinder C, Sweet D,et al. Weight and metabolic changes with Cabotegravir+Rilpivirine long-acting or Bictegravir. Conference on Retroviruses and Opportunistic Infections. Seattle, USA, 2023.